-
Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
03 Feb 2026 15:43 GMT
… Aboutthe Bristol Myers Squibb-Johnson & Johnson Collaboration
Bristol Myers Squibb and … Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb … PHARMACEUTICAL HEALTH
SOURCE: Bristol Myers Squibb
Copyright Business Wire …
-
STAT+: Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s
02 Feb 2026 17:14 GMT
… soils of Easter Island. For Bristol Myers Squibb, an industry stalwart in … side effects.
Later this year, Bristol will get the results from …
-
Piper Sandler Raises Bristol Myers (BMY) PT to $66 Citing Pipeline Visibility
01 Feb 2026 19:07 GMT
Bristol Myers Squibb Company (NYSE:BMY) is … ’s price target for Bristol Myers Squibb Company (NYSE:BMY) … 12, Leerink highlighted that Bristol Myers expects 12 registrational … distinct assets throughout 2026. Bristol Myers Squibb Company (NYSE:BMY) discovers …
-
Bristol Myers Approaches SC to Halt Zydus' Biosimilar Nivolumab Sale
30 Jan 2026 16:50 GMT
New Delhi: Bristol Myers Squibb has approached the Supreme Court … before the apex court, Bristol Myers Squibb has argued that Zydus’s … the relevant patent protections for Bristol Myers Squibb’s original nivolumab product …
-
Bristol Myers moves SC to stop Zydus from selling biosimilar cancer drug
29 Jan 2026 20:23 GMT
New Delhi: US-based Bristol Myers Squibb (BMS) on Thursday filed a … will hear BMS firm ER Squibb's appeal against Zydus … for the remaining term of Squibb's patent, which will … pending post-grant opposition against Squibb's patent filed by …
-
Brandon Hall Group Prepared to Host 2026 HCM Excellence Conference Next Week
03 Feb 2026 15:39 GMT
… and Operations, Medical Excellence, Bristol Myers Squibb
Mike Vaughan, Chief Executive Officer …
-
Sanders report details how Trump broke promises to patients
03 Feb 2026 16:03 GMT
… $8,900 in Japan.
Bristol Myers Squibb charges Americans $544,000 for …
-
Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus
03 Feb 2026 14:29 GMT
… expired on its acquisition by Bristol-Myers Squibb (BMS) in 2009. Under …
-
EMA OKs Dual Therapy for Young Hodgkin Lymphoma Patients
03 Feb 2026 15:17 GMT
… approval of Opdivo (nivolumab, Bristol Myers Squibb Pharma EEIG) in combination with …
-
Antimicrobials Market Valuation, ROI Potential & Long-Term Growth Prospects 2026–2036
03 Feb 2026 11:48 GMT
… , Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, and Boehringer Ingelheim International …
About
© 1995-2026